In another work the introduction of alternative protein markers besides cytokeratins (CKs), such as the glycolysis enzyme hexokinase 2 (HK2), increased the detection of CTCs in a cohort of 18 stage III lung adenocarcinoma patients without clinical evidence of distant metastases from 39% when considering CKposCD45neg to 61% when considering HK2highCD45neg cell subsets [81]. The gene discussed is HK2; the disease is lung adenocarcinoma.